Study at a glance
How might liver disease affect vitamin D availability?
This review brings together selected studies of vitamin D in fatty liver disease, hepatitis C and cirrhosis, which is advanced liver scarring. It examines liver tissue, blood proteins that carry vitamin D, and health outcomes. These are different questions. Finding a vitamin D-related protein in tissue does not measure how much vitamin D that tissue converts.
What did tissue and blood studies in liver disease show?
One biopsy study found a lower proportion of bile-duct cells containing the protein that receives vitamin D signals in people with inflammatory fatty liver disease. It did not find significantly lower staining for two conversion enzymes or lower average blood vitamin D in that group. Among 82 people with cirrhosis, those with less albumin, a blood protein, had lower total vitamin D and less vitamin D that was unbound, meaning not attached to proteins. The unbound percentage was higher, but the actual unbound amount was lower. A separate comparison with people without cirrhosis found a different pattern. Different groups and measurement methods prevent a single conclusion for all liver disease.
Did vitamin D improve liver outcomes?
In a study following 199 people with cirrhosis, the link between low vitamin D and death was uncertain after accounting for several other factors. A trial assigned 65 adults with diabetes and fatty liver to vitamin D3 or placebo for 24 weeks. Vitamin D blood levels rose, but the trial did not demonstrate an improvement in liver fat measured by scanning. Its small size and incomplete follow-up limit the conclusion; it did not prove that all possible effects were absent.
Does a low vitamin D blood result show that supplements will help liver disease?
A low total blood result does not by itself reveal vitamin D delivery to tissues or prove that supplements will improve liver disease. Calculated and directly measured unbound vitamin D can differ, and neither is automatically the better guide to health outcomes. These studies do not establish a universal blood target or vitamin D as a liver treatment.
Read the full article below ↓Liver disease can affect the interpretation of vitamin D through several distinct processes: changes in liver cells, altered carrier proteins and differences in circulating metabolites. These processes should be examined separately before being connected. This review develops the disease-specific evidence within Vitamin D and Liver Function, including metabolic liver disease and cirrhosis. For the shorter version, see Liver Disease, Carrier Proteins and Vitamin D Availability: Study Summary.
Different liver conditions ask different questions
The biopsy study discussed here uses the historical terms nonalcoholic fatty liver disease, or NAFLD, and nonalcoholic steatohepatitis, or NASH. NASH describes fatty liver with inflammatory injury. Chronic hepatitis C is a viral condition. Cirrhosis describes advanced structural scarring and can arise from different causes. Keeping the study populations under their original definitions avoids silently treating these conditions as interchangeable.
Hepatic synthetic dysfunction means impaired production of substances normally made by the liver. That question differs from whether a particular liver cell expresses a vitamin D-related protein. A biopsy can identify staining in a cell population; a blood test can identify a circulating concentration; neither automatically establishes the other. The general conversion pathway is explained in Vitamin D Activation.
This is a narrative appraisal of selected mechanistic, measurement, observational and intervention studies. It is not a systematic treatment review. Its central purpose is to explain what the liver-disease setting changes about the interpretation of vitamin D, and which conclusions require evidence beyond a low total blood concentration.
Biopsies show a tissue-specific pattern
Barchetta and colleagues studied 25 people with biopsy-confirmed NASH, 36 with chronic hepatitis C and 20 surgical comparison participants without liver injury. Biopsies were obtained in winter; advanced Child-Pugh B/C cirrhosis was excluded. A blinded pathologist assessed histology, and immunohistochemistry measured staining for the vitamin D receptor, CYP2R1 and CYP27A1. In NASH, the mean percentage of receptor-positive bile-duct epithelial cells was 63.6%, versus 92.2% in controls. These percentages concern cells, not the proportion of patients who responded to treatment.
The NASH group did not show a statistically significant reduction in CYP2R1 or CYP27A1 staining versus controls, and mean blood 25(OH)D3 was similar. In hepatitis C, CYP2R1 staining correlated with circulating 25(OH)D3, while CYP27A1 staining was inversely associated with fibrosis stage. These are distinct findings in separate disease groups, not proof that all diseased livers lose conversion capacity.
The inference is narrower than “vitamin D deficiency causes liver damage”. Staining identifies a protein signal in sampled tissue, and a cross-sectional comparison cannot establish whether an expression change preceded injury or followed it. It also cannot show how much substrate an enzyme converted. The relevance of local handling is developed in Vitamin D Metabolism at the Cellular Level.
The comparison group deserves attention because surgical participants are selected patients rather than a random sample of healthy people. Differences in how patients enter a study can affect what a comparison means. Likewise, a small biopsy represents a small part of an organ. Neither issue invalidates tissue evidence; both explain why it should be integrated with functional measurements rather than promoted into a complete description of hepatic vitamin D metabolism.
For example, the comparison participants had a mean body mass index of 35.8 kg/m², compared with 30.5 in the NASH group. “No liver injury” therefore did not mean “lean”. A reader who silently assumes lean controls would be analysing a different comparison from the one actually performed. This illustrates why participant characteristics belong alongside the histology findings.
Carrier proteins change the meaning of a total concentration
Total 25(OH)D includes protein-bound and unbound metabolite. The free concentration is the amount unbound per volume of blood; the free percentage is that amount expressed as a fraction of the total. These are different quantities. The underlying binding framework is explained in Vitamin D Binding Protein Explained and Vitamin D Transport Proteins.
A numerical illustration makes the distinction clear. If an imaginary total pool falls from 100 units to 50, while the unbound amount falls from two units to 1.5, the free percentage rises from 2% to 3% despite a lower absolute free amount. Those numbers are illustrative, not study measurements. A higher percentage alone cannot establish preserved availability, and a lower total concentration alone cannot quantify tissue exposure.
The term “bioavailable” needs equal care. It may describe a binding-based calculation, but the name does not mean that a study measured uptake in every tissue or the response of every vitamin D receptor. The existing Full Study of free, albumin-bound and total vitamin D in blood covers those circulating compartments. The additional question here is what happens when liver disease changes their context.
The cirrhosis study found lower total and lower absolute free levels
Lai and colleagues analysed 82 cirrhosis outpatients after excluding six of 88 recruits whose creatinine exceeded 1.5 mg/dL. Median age was 59.9 years; 48 had hepatitis C and 38 used vitamin D supplements. A single blood sample was assessed using total and directly measured free 25(OH)D assays. Albumin divided the cohort into 54 participants at or below 3.5 g/dL and 28 above it.
Compared with the higher-albumin group, the low-albumin group had median total 25(OH)D of 12.1 versus 21.7 ng/mL, free 25(OH)D of 6.2 versus 8.6 pg/mL, and binding protein of 91.4 versus 140.3 μg/mL; each comparison had P<0.01. The free percentage was higher. Both total and free measurements showed inverse associations with parathyroid hormone in the higher-albumin group, but not the low-albumin group. The study did not measure fractures or bone density.
The result directly prevents an overly reassuring interpretation: less carrier protein did not preserve the absolute free concentration in this comparison. It also prevents an overly simple treatment inference. A difference in a biomarker relationship does not establish that raising one concentration will restore bone function. Parathyroid hormone is a regulatory signal, and its relationship with vitamin D cannot substitute for measured clinical outcomes.
Albumin is a useful grouping variable, but it is not a controlled intervention or a pure measure of one biological mechanism. Disease severity and other influences can accompany lower albumin. A comparison organised around albumin therefore cannot assign every vitamin D difference to reduced carrier production. It describes a physiological setting in which the usual interpretation may become less straightforward.
The low-albumin group also had a higher median MELD score, 14 versus nine; MELD is a measure of liver disease severity. In addition, measuring a lower circulating carrier concentration is different from measuring its production rate. The blood measurement records the amount present, which reflects more than synthesis alone. The study did not directly quantify how quickly the liver manufactured binding protein.
Similarly, finding an association in one subgroup and no statistically significant association in another does not, by itself, prove that the two associations differ. That conclusion requires an appropriate comparison between them. The pattern is a reason to investigate altered regulation, not permission to treat a subgroup P value as a complete demonstration of a new mechanism.
Direct measurement and calculation answer related but different questions
Schwartz and colleagues found that calculated free 25(OH)D generally exceeded direct measurements. Their results table compared 24 cirrhosis patients with albumin below 2.9 g/dL against 107 participants without cirrhosis or pregnancy, alongside a separate pregnancy group. Mean measured free 25(OH)D was higher in cirrhosis, 6.3 versus 4.5 pg/mL, despite lower total 25(OH)D.
That direction differs from Lai’s comparison within a cirrhosis cohort. It is not the same contrast: comparing two severity groups within one disease differs from comparing diseased and non-diseased groups. The studies also used different total-vitamin-D assays. These differences are reasons to examine the designs; they do not prove which feature explains the different findings. Neither study measured vitamin D delivery to every tissue.
A calculation imports assumptions about binding and the accuracy of its input measurements. Direct measurement has its own analytical limitations. Neither approach earns clinical superiority from its name alone. To decide which better represents a meaningful outcome, a study must compare performance against that outcome in the population of interest. The wider measurement question is discussed in the evidence synthesis on free and total vitamin D, binding and measurement.
This distinction also helps explain why apparently different studies cannot be reconciled by selecting whichever result supports a preferred conclusion. Differences in disease severity, comparison groups, assays and endpoints need examination first. Repeating the phrase “free vitamin D” does not establish that two investigators measured the same physiological problem with equivalent methods.
Association with disease severity is not proof of a treatment effect
Paternostro and colleagues followed a cirrhosis cohort of 199 patients. Deaths occurred in 26 of 79 participants with 25(OH)D below 10 ng/mL and 16 of 120 in the higher group. After adjustment for age, liver cancer, clinically significant portal hypertension and Child-Pugh severity, the vitamin D hazard ratio was 1.86, with a 95% confidence interval of 0.974 to 3.552 and P=0.060. The adjusted interval included no association.
The unadjusted contrast and adjusted uncertainty both belong in the account. The findings are compatible with vitamin D status reflecting a wider illness context; they do not prove that changing vitamin D would change survival. Adjustment addresses specified measured variables, not every possible influence. A biomarker may be informative about disease severity without being the intervention that reverses that severity.
A supplementation trial separates a blood response from a liver response
In Barchetta’s 2016 double-blind trial, 65 adults with type 2 diabetes and fatty liver were assigned 2,000 IU/day cholecalciferol or placebo for 24 weeks. Twenty-six of 29 treated participants and 29 of 36 controls completed follow-up. Returned vials assessed adherence. Mean 25(OH)D in the treated group rose from 48.15 to 89.80 nmol/L. However, the baseline-adjusted difference in MRI-measured hepatic fat fraction was 0.63 percentage points, with a 95% confidence interval from −1.6 to 2.8 and P=0.57.
This distinguishes a successful change in the circulating marker from a demonstrated improvement in the primary liver endpoint. The trial did not establish equivalence, and its modest sample, incomplete follow-up and selected population limit generalisation. It also did not use repeat biopsies to assess tissue changes. The regimen is a description of a research intervention, not a dosing instruction.
The confidence interval helps explain the remaining uncertainty. A non-significant average difference is compatible with a range of effects, including some improvement and some worsening on the measured scale. It should therefore be read alongside the size of effects that would matter clinically. Nor can an MRI fat measurement answer the separate question of whether fibrosis or clinical liver complications change over a longer period.
What these findings mean together
The evidence addresses three levels: local cellular expression, circulating transport and measured outcomes. A signal at one level does not automatically establish a change at the next. The biopsy findings cannot diagnose conversion failure in all fatty liver disease; the carrier findings cannot establish preserved tissue action; and an increase in blood 25(OH)D cannot stand in for improvement in liver fat, fibrosis, bone health or survival.
The practical scientific conclusion is that liver disease supplies essential context, but does not create one universal interpretation of vitamin D. Disease type and severity, the measured metabolite, carrier proteins, assay method and the outcome under discussion must remain explicit. These studies support more careful interpretation. They do not, by themselves, validate a universal free-vitamin-D target, establish supplementation as liver treatment or justify abandoning assessment of nutritional deficiency.
Scientific sources
Barchetta I et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology. 2012;56(6):2180 to 2187. DOI: 10.1002/hep.25930.
Lai JC et al. Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction. Liver International. 2015;35(10):2294 to 2300. DOI: 10.1111/liv.12819.
Schwartz JB et al. A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. Journal of Clinical Endocrinology & Metabolism. 2014;99(5):1631 to 1637. DOI: 10.1210/jc.2013-3874.
Paternostro R et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wiener klinische Wochenschrift. 2017;129:8 to 15. DOI: 10.1007/s00508-016-1127-1.
Barchetta I et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine. 2016;14:92. DOI: 10.1186/s12916-016-0638-y.
Related reading
Adherence to oxidative balance scores and lower odds of non-alcoholic fatty liver disease: a case-control study
The purpose of this study was to investigate the associations between the oxidative balance scores (OBS) and the risk of NAFLD.
Original paper ↗Read more →Aerobic training with moderate or high doses of vitamin D improve liver enzymes, LXRα and PGC-1α levels in rats with T2DM
The D + AT + HD and D + AT + MD groups had lower levels of ALT and AST enzymes compared to the other groups with no significant difference between D + AT + HD and D + AT + MD.
Original paper ↗Read more →Alterations of liver enzymes and lipid profile in response to exhaustive eccentric exercise: vitamin D supplementation trial in overweight females with non-alcoholic fatty liver disease
This study aimed to investigate the effect of short-term supplementation of Vit D on the liver enzymes and lipid profile alterations following EEE in overweight women with NAFLD.
Original paper ↗Read more →Are Nonalcoholic Fatty Liver Disease and Bone Mineral Density Associated?: A Cross‐Sectional Study Using Liver Biopsy and Dual‐Energy X‐Ray Absorptiometry
Our study aim was to assess bone mineral density (BMD) in patients with biopsy‐proven NAFLD and examine if the severity of NAFLD affects BMD.
Original paper ↗Read more →Associations between dietary total antioxidant capacity and odds of non-alcoholic fatty liver disease (NAFLD) in adults: a case-control study
The aim of this study was to assess relationships between DTAC and odds of NAFLD in a case: control study.
Original paper ↗Read more →Cross-sectional analysis of the health profile and dietary intake of a sample of Canadian adults diagnosed with non-alcoholic fatty liver disease
The aim of this study is to characterize the dietary intake of a sample of Canadian adults diagnosed with NAFLD and examine the correlations with markers of liver health.
Original paper ↗Read more →Effect of Oral and parenteral routes of vitamin D supplementation on serum 25(OH) vitamin D levels in patients with non-alcoholic fatty liver disease
Therefore, this study aimed to compare the efficacy of oral and parenteral routes of vitamin D supplementation on serum 25(OH) vitamin D levels in patients with NAFLD.
Original paper ↗Read more →Elevated remnant cholesterol is linked to non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
The aim of this study was to investigate the association between remnant cholesterol (RC) levels and non-alcoholic fatty liver disease (NAFLD) in patients diagnosed with type 2 diabetes mellitus (T2DM).
Original paper ↗Read more →Genetically determined circulating micronutrients and the risk of nonalcoholic fatty liver disease
We aimed to elucidate the causal relationships using Mendelian randomization (MR).
Original paper ↗Read more →Interaction Between Vitamin D Metabolism Genetic Variants: Association with Hypovitaminosis D, Rheumatoid Arthritis, and Its Clinical Disease Activity
Among the environmental susceptibility factors for the disease, hypovitaminosis D is more frequent in RA patients compared to the healthy population.
Original paper ↗Read more →Low Vitamin D Status Is Associated with Nonalcoholic Fatty Liver Disease Independent of Visceral Obesity in Korean Adults
A total of 1081 adults were enrolled from a population-based cohort in Ansan city.
Original paper ↗Read more →No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
This randomized, double-blind, placebo-controlled trial was carried out at the Diabetes Centre of Sapienza University, Rome, Italy, to assess oral treatment with cholecalciferol (2000 IU/day) or placebo in T2D patients with NAFLD.
Original paper ↗Read more →Non Alcoholic Fatty Liver Disease Is Positively Associated with Increased Glycated Haemoglobin Levels in Subjects without Diabetes
Screening for non-alcoholic fatty liver disease (NAFLD) is key step for primary management of fatty liver in the clinical setting.
Original paper ↗Read more →Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia
Few previous studies have investigated whether NAFLD could be independently associated with cognitive impairment.
Original paper ↗Read more →Relationship between sarcopenia and fatty liver in middle-aged and elderly patients with type 2 diabetes mellitus
In this study, we investigated the relationship between sarcopenia and fatty liver in middle-aged and elderly patients diagnosed with type 2 diabetes mellitus (T2DM) to provide a theoretical foundation for the prevention and treatment of sarcopenia.
Original paper ↗Read more →Relationship of Vitamin D Deficiency and Fatty Liver in Children as Defined by Multiple Imaging and Histologic Endpoints
All participants had liver imaging, namely, controlled attenuation parameter to assess steatosis and, to assess fibrosis, vibration controlled transient elastography (FibroScan), and acoustic radiation force impulse imaging.
Original paper ↗Read more →Serum 25-hydroxyvitamin D and metabolic syndrome: a large cross-section study with dose response analysis in a health screening population
This study aimed to investigate the independent and potential non-linear association between serum 25(OH)D levels and MetS in adults undergoing routine health examinations.
Original paper ↗Read more →Temporal trend of serum vitamin profiles and the association with non-alcoholic fatty liver disease
This study aimed to characterize temporal trends of serum vitamins (A, B9, B12, D, E) among Chinese adults undergoing health examinations (2015 to 2023) and explore their associations with NAFLD.
Original paper ↗Read more →The Effect of Non-Alcoholic Fatty Liver Disease on Weight Loss and Resolution of Obesity-Related Disorders After Bariatric Surgery
Only hyperlipidemia was significantly associated with NASH compared to the groups with no NASH or borderline NASH (p value = 0.002 and p value = 0.04, respectively) during the first two years of follow-up.
Original paper ↗Read more →The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs
Eight randomized controlled trials with a total of 657 patients are included.
Original paper ↗Read more →The Role of Vitamin D in Obese Children with Non-Alcoholic Fatty Liver Disease and Associated Metabolic Syndrome
Anthropometric and paraclinical data associated with MS were statistically compared before and after treatment.
Original paper ↗Read more →Original sources
Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus
Published in Hepatology (2012).
Publication details
Barchetta I et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology. 2012;56(6):2180 to 2187. DOI: 10.1002/hep.25930.
Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction
Published in Liver International (2015).
Publication details
Lai JC et al. Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction. Liver International. 2015;35(10):2294 to 2300. DOI: 10.1111/liv.12819.
A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations
Published in Journal of Clinical Endocrinology & Metabolism (2014).
Publication details
Schwartz JB et al. A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations. Journal of Clinical Endocrinology & Metabolism. 2014;99(5):1631 to 1637. DOI: 10.1210/jc.2013-3874.
Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis
Published in Wiener klinische Wochenschrift (2017).
Publication details
Paternostro R et al. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wiener klinische Wochenschrift. 2017;129:8 to 15. DOI: 10.1007/s00508-016-1127-1.
No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Published in BMC Medicine (2016).
Publication details
Barchetta I et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine. 2016;14:92. DOI: 10.1186/s12916-016-0638-y.